Page 2 - Subgroup Analysis News Today

Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Brutons tyrosine kinase...

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...

Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)

Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were...

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.